Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: A review of HEPLISAV™ safety and efficacy

Expert Review of Vaccines

Volumn 10, Issue 4, 2011, Pages 417-427

  Cooper, Curtis ^a   MacKie, David ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

adjuvant; hepatitis B virus; immunostimulatory sequence; ISS; vaccine

Indexed keywords

ALUMINUM DERIVATIVE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOFERON; IMMUNOLOGICAL ADJUVANT; LEVAMISOLE; PHOSPHORYL LIPID A; PLACEBO; PLASMID DNA; RECOMBINANT HEPATITIS B VACCINE;

ADAPTIVE IMMUNITY; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; DNA SEQUENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; PREVALENCE; PRIORITY JOURNAL; VACCINATION; WEGENER GRANULOMATOSIS;

ADJUVANTS, IMMUNOLOGIC; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 79955088827     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.162     Document Type: Article

References (55)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11(2), 97-107 (2004). (Pubitemid 38365759)
2. Hepatitis B vaccines. Wkly Epidemiol. Rec. 84(40), 405-419 (2009).
3. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis. 14(1), 1-21, VII (2010).
4. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28, 112-125 (2006). (Pubitemid 44289094)
5. Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R. D. 9(3), 137-145 (2008). (Pubitemid 351651997)
6. Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther. 7(11), 1731-1737 (2007). (Pubitemid 350157498)
7. Hepatitis B. World Health Organization Fact Sheet 204. World Health Organization, Geneva, Switzerland (2008).
8. Goldstein ST, Zhou F, Hadler SC et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34(6), 1329-1339 (2005). (Pubitemid 41819540)
9. Shouval D. Hepatitis B vaccines. J. Hepatol. 39(Suppl. 1), 7 (2003).
10. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006). (Pubitemid 44307383)
11. Rots NY, Wijmenga-Monsuur AJ, Luytjes W et al. Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations. Vaccine 28(4), 893-900 (2010).
12. Shiffman ML. Management of acute hepatitis B. Clin. Liver Dis. 14(1), 75-91; VIII-IX (2010).
13. Thomas DL, Di Bisceglie AM, Alter HJ, Terrault NA. Understanding the natural history of chronic HBV and HCV infections. J. Fam. Pract. 59(Suppl. 4), S17-S22 (2010).
14. Chen DS. Toward elimination and eradication of hepatitis B. J. Gastroenterol. Hepatol. 25(1), 19-25 (2010).
15. Girndt M, Litjens N. Unmet needs and new promises in hepatitis B vaccination for chronic kidney disease patients. European Nephrology 4, 5 (2010).
16. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1(5), 377-385 (1981). (Pubitemid 12218155)
17. Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J. Hepatol. 50(4), 805-816 (2009).
18. Floreani A, Baldo V, Cristofoletti M et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 22(5-6), 607-610 (2004). (Pubitemid 38114889)
19. Ni YH, Huang LM, Chang MH et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132(4), 1287-1293 (2007).
20. Roznovsky L, Orsagova I, Kloudova A et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 38(5), 395-400 (2010).
21. Burgess MA, Rodger AJ, Waite SA, Collard F. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine 19(32), 4835-4841 (2001). (Pubitemid 32800770)
22. Gilbert C, Villa G, Klopfer S, Schodel F, Bhuyan P. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal predialysis and dialysis patients. Presented at: Infectious Disease Society Annual Meeting. Philadelphia, PA, USA, 29 October-1 November 2009.
23. Vlassopoulos D. Recombinant hepatitis B vaccination in renal failure patients. Curr. Pharm. Biotechnol. 4(2), 141-151 (2003). (Pubitemid 36416870)
24. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21(31), 4604-4608 (2003). (Pubitemid 37315782)
25. Fazle Akbar SM, Furukawa S, Yoshida O et al. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J. Hepatol. 47(1), 60-66 (2007). (Pubitemid 46817695)
26. Cruciani M, Mengoli C, Serpelloni G et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 25(4), 709-718 (2007). (Pubitemid 44873151)
27. Products discontinued from the market since the publication of the 2000 CPS. In:Compendium of Pharmaceuticals and Specialties. CPS (Eds).Canadian Pharmacists Association, Canada (2010).
28. Fabrizi F, Dixit V, Messa P, Martin P. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment. Pharmacol. Ther. 32(6), 756-762 (2010).
29. Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus 18(13), 1127-1128 (2009).
30. Perez-Garcia R, Perez-Garcia A, Verbeelen D et al. AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int. 61(5), 1845-1852 (2002). (Pubitemid 34437940)
31. Majano P, Roda-Navarro P, Alonso- Lebrero JL et al. AM3 inhibits HBV replication through activation of peripheral blood mononuclear cells. Int. Immunopharmacol. 4(7), 921-927 (2004). (Pubitemid 38739097)
32. Bienzle U, Gunther M, Neuhaus R et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38(4), 811-819 (2003). (Pubitemid 37221664)
33. Davis HL, Weeratna R, Waldschmidt TJ et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160(2), 870-876 (1998). (Pubitemid 28049329)
34. Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273(5273), 352-354 (1996). (Pubitemid 26250262)
35. Madaan A. Heplisav. Drugs Future 34(7), 5 (2009).
36. Sung JJ, Lik-Yuen H. HBV-ISS (Dynavax).Curr. Opin. Mol. Ther. 8(2), 150-155 (2006).
37. Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev. Vaccines 6(5), 747-759 (2007). (Pubitemid 47607850)
38. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell. Immunol. 167(1), 72-78 (1996). (Pubitemid 26048848)
39. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
40. Martin-Orozco E, Kobayashi H, Van Uden J et al. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. 11(7), 1111-1118 (1999). (Pubitemid 29338753)
41. Halperin SA, Van Nest G, Smith B et al. A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21(19-20), 2461-2467 (2003). (Pubitemid 36561337)
42. Halperin SA, Dobson S, McNeil S et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24(1), 20-26 (2006). (Pubitemid 41721097)
43. Halperin SA, Diaz-Mitoma F, Martin T, De Boer AW. Immunogenicity and safety of an investigational hepatitis B vaccine. Presented at: Fifth Decennial International Conference on Healthcare-Associated Infections (ICHAI).Atlanta, GA, USA, 18-22 March 2010.
44. McNeil S, Halperin SA, Hart R et al. Safety and immunogenicity of a novel hepatitis B vaccine adjuvanted with immunostimulatory sequence (ISS) in renal predialysis and dialysis patients. Presented at: National Kidney Foundation Spring Meetings. Orlando, FL, USA, 15-17 April 2010.
45. Figueroa A. Dynavax and Merck provide update on US FDA clinical hold on investigational vaccine HEPLISAV™. In:Liver Disease/Hepatitis News - Medical News Today. Nordqvist C (Ed.).MediLexicon International Ltd, London, UK (2008).
46. de Boer AW, McNeil S, Lunde N et al. Two clinical trials exploring safety and immunogenicity of a novel hepatitis B vaccine adjuvanted with immunostimulatory sequence in patients with chronic renal failure. Presented at: The 47th European Renal Association - European Dialysis and Transplant Association Joint Congress. Munich, Germany, 25-28 June 2010.
47. McNeil S, Halperin SA, Hart R et al. Preliminary results from two studies comparing immunogenicity of three doses of HBsAg combined with immunostimulatory sequence (ISS) in chronic renal failure (CRF) patients. Presented at: 47th Annual Meeting of the Infectious Disease Society of America (IDSA).Philadelphia, PA, USA, 29 October-1 November 2009.
48. Clarke T. FDA gives Dynavax OK to resume hepatitis B trials. In:Reuters. Lewis M (Ed.).Thomson Reuters, Boston, MA, USA (2009).
49. Stynes T. Dynavax may seek FDA approval for heplisav earlier than expected. In:Company News. Newswires DJ (Eds).Dow Jones & Company, Inc., New York, NY, USA (2010).
50. Ambrosch F, Wiedermann G, Kundi M et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 18(20), 2095-2101 (2000). (Pubitemid 30129098)
51. Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad. Med. J. 63(Suppl. 2), 169-177 (1987).
52. Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769-2778 (1999). (Pubitemid 29323002)
53. Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 21(1), 71-76 (2007). (Pubitemid 44912539)
54. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin. Infect. Dis. 46(8), 1310-1314 (2008). (Pubitemid 351589919)
55. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm. Rep. 55(RR-16), 1-33 (2006).